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Abstract
Purpose Anchored electromagnetic transponders for tumor
motion monitoring during lung radiotherapy were clinically
evaluated. First, intrafractional motion patterns were ana-
lyzed as well as their interfractional variations. Second, in-
tra- and interfractional changes of the geometric transpon-
der positions were investigated.
Materials and methods Intrafractional motion data from
7 patients with an upper or middle lobe tumor and three
implanted transponders each was used to calculate breath-
ing amplitudes, overall motion amount and motion midlines
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in three mutual perpendicular directions and three-dimen-
sionally (3D) for 162 fractions. For 6 patients intra- and
interfractional variations in transponder distances and in
the size of the triangle defined by the transponder locations
over the treatment course were determined.
Results Mean 3D values of all fractions were up to 4.0,
4.6 and 3.4 mm per patient for amplitude, overall motion
amount and midline deviation, respectively. Intrafractional
transponder distances varied with standard deviations up to
3.2 mm, while a maximal triangle shrinkage of 36.5% over
39 days was observed.
Conclusions Electromagnetic real-time motion monitoring
was feasible for all patients. Detected respiratory motion
was on average modest in this small cohort without lower
lobe tumors, but changes in motion midline were of the
same size as the amplitudes and greater midline motion can
be observed in some fractions. Intra- and interfractional
variations of the geometric transponder positions can be
large, so for reliable motion management correlation be-
tween transponder and tumor motion needs to be evaluated
per patient.
Keywords Intrafraction motion · Lung radiotherapy ·
Electromagnetic tracking · Stability of marker positions ·
Motion management
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Bewegungsdetektion während der
Strahlentherapie der Lunge mit verankerten
elektromagnetischen Transpondern
Quantifizierung von inter- und intrafraktioneller Bewegung
und Variabilität der relativen Transponderpositionen
Zusammenfassung
Ziel Verankerte, elektromagnetische Transponder für die
Bewegungserkennung des Tumors während der Strahlen-
therapie der Lunge wurden klinisch evaluiert. Dafür wurden
intrafraktionelle Bewegungsmuster und ihre interfraktionel-
len Variationen analysiert und intra- und interfraktionelle
Veränderungen der geometrischen Transponderpositionen
untersucht.
Material und Methoden Intrafraktionelle Bewegungsdaten
von 7 Patienten mit einem Ober- oder Mittellappentumor
und je drei implantierten Transpondern wurden benutzt,
um Atemamplituden, Gesamtbewegungsaufkommen und
Bewegungsmittellinien für die drei zueinander senkrech-
ten Bewegungsrichtungen und dreidimensional (3D) in
162 Fraktionen zu berechnen. Für 6 Patienten wurden
intra- und interfraktionelle Variationen der Transponderab-
stände und der Größe des von den Transponderpositionen
definierten Dreiecks im Therapieverlauf bestimmt.
Ergebnisse Die mittleren 3D-Werte aller Fraktionen pro
Patient ergaben bis zu 4,0, 4,6 und 3,4 mm für Amplitu-
de, Gesamtbewegungsaufkommen und Mittellinienverände-
rung. Intrafraktionelle Transponderabstände variierten mit
Standardabweichungen von bis zu 3,2 mm, während eine
maximale Verkleinerung der Dreiecksgröße um 36,5 % über
39 Tage beobachtet wurde.
Schlussfolgerung Elektromagnetische Echtzeit-Bewe-
gungserkennung war für alle Patienten durchführbar. In
dieser kleinen Patientenkohorte ohne Unterlappentumore
war die detektierte Atembewegung im Mittel moderat. Je-
doch waren Veränderungen der Bewegungsmittellinie in
der gleichen Größe wie die Atemamplituden; in einzelnen
Fraktionen konnten größere Mittellinienbewegungen beob-
achtet werden. Intra- und interfraktionelle Variationen der
geometrischen Transponderpositionen können erheblich
sein, so dass für ein zuverlässiges Bewegungsmanagement
die Korrelation zwischen Transponder- und Tumorbewe-
gung für jeden Patienten untersucht werden sollte.
Schlüsselwörter Intrafraktionelle Bewegung ·
Strahlentherapie der Lunge · Elektromagnetisches
Tracking · Stabilität von Markerpositionen ·
Bewegungsmanagement
Radiotherapy is a cornerstone of curative intent treatment
for early and advanced lung cancer, see e. g. [1–6]. Thereby
intrafractional tumor motion is a main challenge because it
potentially causes deviations between the planned and de-
livered doses in high precision therapy [7]. A new method
for three-dimensional (3D) real-time lung tumor motion
monitoring without imaging dose is the continuous detec-
tion of implanted anchored electromagnetic transponders
[8] available for the Calypso® system (Varian Medical Sys-
tems, Inc., Palo Alto, CA, USA). These transponders have
a capsule with expandable nitinol legs for fixation in small
airways and are implanted in lung tissue bronchoscopically
under continuous fluoroscopic guidance within 3 cm dis-
tance to the lesion. Recently, a report of the first patient
treated with multileaf collimator (MLC) tracking based on
them was published [9]. Here we report the evaluation of
collected motion data from patients studied at our center
who have been enrolled in a multicenter trial investigating
safety and stability of the anchored transponders in a wider
patient collective. Each patient had three transponders im-
planted and the Calypso® system reported single transpon-
der as well as transponder-centroid translations in lateral,
longitudinal and vertical direction. Each transponder was
updated with a rate of approximately 3.3 Hz, leading to
a continuously updated centroid position of approximately
10 Hz, always using the latest position information of each
transponder. With this data we were able to quantify the
intrafractional motion during lung treatments and their in-
terfractional variations. Additionally, we evaluated the sta-
bility of intrafractional motion within fractions because all
systems which aim to adapt treatment directly after motion
detection (e. g. MLC tracking [10–12]) need motion predic-
tion due to system latency, see e. g. [13, 14]. The quality of
these predictions depend on intrafractional regularity of the
motion patterns. To study this regularity, motion patterns of
the two patients with the largest 3D amplitudes were fur-
ther analyzed via quantification of changes between adja-
cent beam-on and beam-off phases. Since the transponder-
centroid position is only a surrogate for motion of the lung
lesion, we quantified the intra- and interfractional changes
of individual transponder positions via calculation of inter-
transponder distance variation.
Materials and methods
Patient data
Seven lung cancer patients suffering from an upper or
middle lobe tumor were enrolled at the German Cancer
Research Center within the aforementioned multicenter
trial (ClinicalTrials.gov NCT01396551) organized by Var-
ian Medical Systems, Inc. The trial was approved by the
ethics committee of the medical faculty at Heidelberg
university. Intrafractional motion data of the bronchoscop-
ically implanted electromagnetic transponders was used
for all presented investigations. Two patients received
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Table 1 Results of transponder-centroid motion evaluation for all patients
Patient P1 P2 P3 P4 P5 P6 P7
Tumor position RUL LUL LUL RML LUL RML RML
Evaluated fractions 10 10 31 26 29 29 27
Mean of fraction midline
(mean ± SD) [mm]
Lat 0.0 ± 0.3 –0.2 ± 0.3 0.1 ± 0.4 0.4 ± 0.7 0.4 ± 0.5 0.1 ± 1.5 0.4 ± 0.5
Long 0.7 ± 1.7 –0.1 ± 0.3 0.3 ± 0.5 0.7 ± 0.8 0.2 ± 0.5 –1.0 ± 1.4 0.4 ± 0.5
Vert –1.5 ± 1.6 0.1 ± 0.5 0.0 ± 0.4 0.1 ± 0.4 0.0 ± 1.1 –0.6 ± 1.3 0.0 ± 0.5
3Da 3.4 ± 0.8 0.8 ± 0.3 0.8 ± 0.4 1.3 ± 0.7 1.4 ± 0.6 2.9 ± 1.0 1.0 ± 0.4
SD of fraction midline
(mean ± SD) [mm]
Lat 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.2 0.4 ± 0.2 1.0 ± 0.5 0.4 ± 0.2
Long 1.8 ± 0.4 0.3 ± 0.1 0.3 ± 0.3 0.6 ± 0.3 0.4 ± 0.1 1.2 ± 0.6 0.4 ± 0.2
Vert 1.9 ± 0.9 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.7 ± 0.2 0.9 ± 0.4 0.4 ± 0.1
3Db 1.8 ± 0.5 0.3 ± 0.1 0.4 ± 0.3 0.6 ± 0.3 0.6 ± 0.2 1.2 ± 0.5 0.5 ± 0.2
Mean of overall fraction
motion (mean ± SD) [mm]
Lat, long and vert have the same values as for “Mean of fraction midline”
3D 4.6 ± 0.8 1.5 ± 0.2 0.9 ± 0.4 2.8 ± 0.5 2.1 ± 0.6 3.4 ± 0.9 1.2 ± 0.3
SD of overall fraction
motion (mean ± SD) [mm]
Lat 0.8 ± 0.1 0.9 ± 0.2 0.4 ± 0.1 1.3 ± 0.3 0.7 ± 0.2 1.6 ± 0.4 0.5 ± 0.2
Long 3.1 ± 0.3 0.5 ± 0.1 0.4 ± 0.3 2.4 ± 0.3 0.6 ± 0.2 1.9 ± 0.5 0.7 ± 0.2
Vert 3.0 ± 0.8 1.1 ± 0.2 0.4 ± 0.1 0.5 ± 0.1 1.8 ± 0.5 1.1 ± 0.4 0.6 ± 0.1
3D 2.4 ± 0.4 0.6 ± 0.1 0.4 ± 0.3 1.3 ± 0.4 1.1 ± 0.3 1.5 ± 0.5 0.6 ± 0.2
Amplitude around current
midline (mean ± SD) [mm]
Lat 0.9 ± 0.2 1.1 ± 0.3 0.4 ± 0.1 1.4 ± 0.3 0.8 ± 0.2 1.6 ± 0.3 0.3 ± 0.1
Long 3.1 ± 0.6 0.5 ± 0.1 0.2 ± 0.0 3.2 ± 0.5 0.4 ± 0.2 2.1 ± 0.3 0.7 ± 0.2
Vert 2.7 ± 0.3 1.6 ± 0.2 0.3 ± 0.0 0.5 ± 0.1 2.2 ± 0.7 0.7 ± 0.2 0.5 ± 0.1
3D 4.0 ± 0.6 2.0 ± 0.3 0.5 ± 0.1 3.4 ± 0.5 2.3 ± 0.7 2.8 ± 0.3 0.9 ± 0.2
RUL right upper lobe, LUL left upper lobe, RML right middle lobe, lat lateral, long longitudinal, vert vertical, SD standard deviation, 3D three
dimensional
Referring to the supplementary material:
aMmeanmean ˙ MSDmean
bMmeanSD ˙ MSDSD
hypofractionated 3D conformal radiotherapy (3D CRT) in
10 fractions and 5 patients were treated with step-and-shoot
IMRT in 28–31 fractions. Tumor positions and number of
evaluated fractions for our study are listed in Table 1. For
the evaluations of single transponder motions one IMRT
patient (P5) was excluded because one transponder had
to be omitted for motion monitoring as the distance of it
to one of the other transponders exceeded the maximal
allowed distance of 7.5 cm specified by the manufacturer
[15]. Average delivery time of a treatment fraction was
4.5 min (9.6 min) for 3D CRT (IMRT) patients. For all
investigations single transponder and transponder-centroid
data were linearly interpolated to the same 10 Hz grid to
obtain synchronized information for all transponders and
to equalize the original fluctuations in update rate.
Transponder-centroid motion quantification
The basis of all motion evaluations was the determination of
a transponder-centroid motion midline by calculating a slid-
ing mean for a time window of 10 s, covering 2–3 breathing
cycles. The three-dimensional midline Mft was calculated
for each fraction f for all points in time t between the start
of the first and the end of the last treatment beam, using
detected positions rft including the 5 s before and after this
time interval (equal to 50 data points before and after, be-
cause of the 10 Hz grid). All evaluations were made equiv-
alently for the unidirectional components and the norm Mft
of the vector, which is used for description in this section
and the formulas in the supplementary material.
The midline position for the time the irradiation started
ts was called initial midline: Mfinitial = Mft=ts : The midline
variations per fraction were calculated as mean Mfmean and
standard deviation (SD) MfSD of the midline positions rel-
ative toMfinitial. From these fraction values means and SDs
were calculated per patient to quantify the interfractional
variations of the mean midline deviation (Mmeanmean and MSDmean)
and the interfractional variations of the intrafractional width
of midline positions (MmeanSD and MSDSD).
For quantification of overall motion amount all centroid
positions rft were analyzed in relation to the corresponding
Mfinitial for all three directions separately and in 3D. For
each fraction, means and SDs were calculated and from
these values interfractional means and SDs per patient as
above.
For each in- and exhale peak the distance between rft
and the midline defined for the same point in time Mft was
calculated to determine motion amplitudes in lateral, lon-
gitudinal and vertical direction and in 3D relative to the
actual midline. Data from all peaks were averaged to de-
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Fig. 1 Example of longitudinal transponder-centroid motion for frac-
tion 4 of patient 1. The longitudinal midline and the beam-on times are
also indicated. The initial midline is set to zero. The intervals I1, I2 and
I3 related to the 4th beam-off phase are shown as example.
rive a mean fraction amplitude. From these amplitudes the
mean amplitude per patient was calculated with the corre-
sponding SD.
For investigation of intrafractional changes between ad-
jacent beam-on and beam-off phases motion patterns of the
two patients with the largest 3D amplitudes were further
analyzed. For each beam-off time (lasting about 20 s), three
intervals of the same length I1, I2 and I3 were defined, where
I2 refers to the beam-off interval and I1 and I3 denote the ad-
jacent beam phases before and after the beam-off time. For
these intervals the SD of centroid positions, as surrogate
for overall motion amount and the mean motion midline,
were determined for three mutually perpendicular directions
and in 3D. The differences between these adjacent intervals
were evaluated.
An example of detected motion with plotted midline and
indicated times of irradiation can be found in Fig. 1.
Fig. 2 Transponder-centroid displacements for all patients in three directions and in 3D calculated as deviations from the initial midline for all
fractions (overall motion amount). The box indicates the values between 25 and 75% of the motion data and the vertical line within the box marks
the median. To exclude outliers, the whiskers cover only 99% of the data. Lat lateral, Long longitudinal, Vert vertical, 3D three dimensionally
Intertransponder variations
Variations in transponder positions were evaluated re-
garding intra- and interfractional distance changes. First,
transponder distances were calculated from the interpolated
single transponder data for all points in time between start
of first and end of last beam for all three directions. From
these distances the fraction SDs were calculated.
To study the origin of intrafractional variations, linear
correlations between the longitudinal SDs of transponder
distances and three parameters potentially affecting rela-
tive transponder motion were evaluated. These parameters
were (I) the fraction mean 3D distance of the transpon-
der pair, (II) the mean 3D amplitude of the transponder-
centroid in the corresponding fraction and (III) the product
of (I) and (II).
In addition, the interfractional changes in the individ-
ual transponder positions were analyzed. Therefore 3D
transponder distances were used for determination of the
area of the triangle defined by the location of the transpon-
ders. For each fraction, the mean and SD of the triangle area
were calculated to evaluate the overall trend. Linear regres-
sions of the 3D distances with the day after first fraction
were averaged to determine a mean distance change per
day (6 patients × 3 transponder distances = 18 regressions).
Furthermore, mean 3D transponder distances of the first
fraction were defined as patient-specific initial distances
and it was investigated which percentage of the 381 mean
distances measured in the following fractions were within
1 and 2 mm.
Results
Transponder-centroid motion quantification
The overall motion amount for all patients can be seen in
Fig. 2 as a boxplot of all transponder-centroid positions
relative to the corresponding initial midline. Quantitative
K
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results of the intra- and interfractional changes in motion
midline and overall motion are presented in Table 1 with
the breathing amplitudes. The unidirectional motion mid-
line means of fraction means range from –1.5 to 0.7 mm
with SDs between 0.3 and 1.6 mm representing the inter-
fractional variations. The majority of these means of frac-
tion means are very close to zero as anticipated for a peri-
odic breathing motion. The corresponding calculations for
the mean of overall motion resulted in the same values,
which has to be expected, as the midline mean is calculated
from nearly the same data (plus 5 s in the beginning and
the end of each fraction) using one additional averaging.
The three-dimensional means of fraction means, whose re-
sults are not dominated by the compensation of positive and
negative position values, show values up to 3.4 mm for the
motion midline and up to 4.6 mm for the overall motion.
These values are not the same because of the additional cal-
culation of vector norm, which does not commute with the
averaging. The means and SDs of the fraction SDs in mid-
line and overall motion amount describe the intrafractional
variations and their change between fractions. Because of
the averaging, means of SDs are generally larger for the
overall motion than for the midline. Maximum unidirec-
tional values are 3.0 and 1.9 mm, respectively. Maximum
SD describing interfractional changes is 0.9 mm.
For two of the seven patients no amplitude was observed
to be larger than 1 mm. The maximum unidirectional ampli-
tudes of the other five patients are either in the longitudinal
or the vertical direction, ranging from 1.6 to 3.2 mm. Three-
dimensional amplitudes were observed to be between 0.5
and 4.0 mm, while the interfractional change of amplitudes
was small with all SDs well below 1 mm.
The two patients with the largest 3D amplitude are P1
and P4. The evaluation of motion differences in adjacent
beam-on and beam-off phases considers 3 intervals for each
of the 5 beam-off times per fraction for P1 and 8 beam-
off times per fraction for P4 (all IMRT segments with the
same gantry angle are summarized to one beam including
the short breaks between segments). P1 shows remarkable
deviations between adjacent intervals, e. g. a mean differ-
ence of vertical midline of 1.4 mm and maximum values
of 7.0 mm for longitudinal and 9.1 mm for vertical midline,
while for P4 (second largest motion amount) all studied
differences are negligible.
Intertransponder variations
Intrafractional longitudinal transponder distances vary with
SDs up to 3.2 mm. All lateral and vertical SDs are below
1 mm, hence they were not studied further. Correlation anal-
yses between longitudinal distance SDs with 3D transpon-
der distances (Pearson’s correlation coefficient r = 0.42) and
3D transponder-centroid amplitudes (r = 0.49) show poor
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Fig. 3 Standard deviations (SD) of longitudinal transponder dis-
tances plotted against the product of the mean three-dimensional (3D)
transponder distance and the mean 3D amplitude of the transponder-
centroid for each transponder pair in each fraction of all 6 patients
results, while their product is strongly correlated to the lon-
gitudinal SDs (r = 0.83, p < 0.001). This shows that only
the coincidence of large transponder distances and over-
all motion amount leads to large intrafractional transponder
distance variations. Fig. 3 shows the plot of all longitudi-
nal SDs of all patients against the corresponding product of
mean 3D transponder distance and mean 3D transponder-
centroid amplitude per fraction.
For all 6 patients the transponder triangle area shrank
over the treatment course, see Fig. 4. A maximum decrease
of 36.5% was observed for P7. The triangle shrinkage re-
sulted from heterogeneous interfractional transponder dis-
tance variations; 16 of 18 distances shrank and 2 distances
grew. The mean 3D transponder distance change per day
after first fraction, determined via averaging of regressions,
resulted in –0.07 mm ± 0.08 mm. The largest slope in the
linear regression, namely –0.25 mm per day was found in
P7. Considering all mean 3D transponder distances per frac-
tion, the difference to the first fraction is maximum 1 mm
(2 mm) for 47% (73%) of distances.
Discussion
Transponder-centroid motion quantification
Published analyses of lung tumor motion found an in-
creasing motion amount with decreasing distance to the
diaphragm, e. g. [16]. Because the tumors in the current
work are located in an upper or middle lobe, data from
lower lobe tumors were removed from published data for
comparison, if not stated different. In the current study,
amplitude is defined as distance from midline to peak,
K
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Fig. 4 Triangle area defined
by the transponder positions per
day of all 6 patients (means with
standard deviations depicted by
error bars). Each vertical axis
covers a range of 2 cm2
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while in the image-based data, used for comparison in the
following, a peak-to-peak amplitude is used. Therefore,
current results were doubled for comparison finding good
agreement between image-based and electromagnetically
detected motion. Considering 11 patients from an anal-
ysis using respiration correlated cone-beam CT (CBCT)
[17], mean 3D amplitude extracted from 6 CTs per patient
can be calculated to 3.7 mm ± 3.2 mm. The corresponding
value for our data is 4.5 mm ± 2.5 mm. Mean unidirectional
amplitudes determined from lung marker motion detected
fluoroscopically with 30 Hz [16] result in 1.2 mm ± 0.9 mm,
3.2 mm ± 3.2 mm and 2.6 mm ± 2.2 mm for lateral, longi-
tudinal and vertical motion, respectively, considering only
the 13 patients with tumors in an upper or middle lobe.
Our data results in 1.8 mm ± 1.0 mm, 2.9 mm ± 2.6 mm
and 2.4 mm ± 1.9 mm.
Large intrafractional changes in motion midline were ob-
served, especially in P1, where the mean of midline devia-
tions from fraction specific initial midline over all fractions
is 3.4 mm in 3D. The largest difference in unidirectional
mean midline position between two consecutive intervals
of approximately 20 s was found in the same patient to be
9.1 mm in vertical direction. Maximum longitudinal drift
in mean tumor position determined from repeated 4D CT
scans [18] was 6.9 mm for one lower lobe tumor within
30 min.
These results show the possibility of relevant variations
in motion patterns during a course of treatment. This should
be kept in mind during margin definition for conventional
therapy without continuous motion detection based on one
pretreatment 4D CT as well as for beam-tracking techniques
relying on aforementioned motion prediction methods.
Intertransponder variations
The amount of intrafractional variation in transponder dis-
tances found here depends on the combination of inter-
transponder distance and overall motion amount. As the
motion amount for each patient is unknown before therapy,
the intertransponder distances should be as small as possi-
ble, regarding minimum distance of 1 cm requested by the
system [9]. Concurrently, for good representation of tumor
motion it is desirable to enclose the whole tumor with the
transponders, while the transponder-centroid should be as
close to the tumor-centroid as possible. Since there is no
published data available for intrafractional distance varia-
tions of implanted lung markers, only interfractional varia-
tions in 3D distance found here can be compared with pub-
lished data on bronchoscopically placed gold markers [19].
Reported intermarker distances measured with stereoscopic
fluoroscopic x-ray imaging for 11 hypofractionated patients
during 1 to 2 weeks of treatment differ maximum 1 mm
(2 mm) from the initial distances (determined from plan-
ning CT) for 80% (95%) of 198 measurements in 71 setups.
The fraction mean 3D transponder distances in this work
differs much more from the first fraction with 47% (73%)
for 1 mm (2 mm). But, considering only the first 14 days
after start of treatment, our values increase to 71% (88%)
and for the first 7 days, they grow to 81% (90%). Thus, the
transponder or marker distance changes seem not to arise
from differences in e. g. fixation, but from tissue reaction
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on irradiation (like tumor shrinkage). The extent of these
reactions is larger for longer observation times because of
time needed for tissue response.
Changes in intertransponder distances suggest geometry
variations in the surrounding tissue, possibly modifying the
tumor and organs at risk (OAR) geometry in general and
especially the relationship of transponder-centroid and tu-
mor-centroid from the planning CT. Interfractional marker-
to-tumor-centroid displacements for bronchoscopically im-
planted gold coils, measured in weekly 4D CBCTs over
7 weeks in 7 patients [20], resulted e. g. in a mean 3D dis-
tance change of 5 mm ± 3 mm. A recent study on 71 con-
ventional fractionated lung cancer patients without markers
receiving at least a weekly kV CBCT shows a replanning
necessity in 60% of the patients due to geometrical changes
in tumor or OARs [21].
The Calypso® system measures transponder distances
during the localization procedure of each fraction. This data
can be used to establish geometrical changes within irradi-
ated lung tissue and may be useful as a future surrogate
indicating lung toxicity or therapy response.
Conclusions
Electromagnetic real-time motion monitoring of the transpon-
der-centroid was feasible for all patients. Detected motion
shows that tumor midline motion can be of the same size
as the breathing amplitude. In addition, there can be large
changes between adjacent time intervals. These results
should be kept in mind when choosing treatment tech-
nique, proper margins and tracking method, if available.
Image-based geometry monitoring should be performed
on a regular basis to enable an adaption of treatment to
changed geometry of transponders, tumor and OARs.
Funding We thank the German Research Foundation DFG (SFB/TRR
125) for partly funding this project. In addition, we thank Varian Med-
ical Systems, Inc. for organizing the multicenter trial and providing
the transponders and support for transponder implantation and motion
monitoring application.
Compliance with ethical guidelines
Conflict of interest D. Schmitt, S. Nill, F. Roeder, D. Gompelmann,
F. Herth and U. Oelfke declare that they have no competing interests.
Ethical standards All procedures performed in studies involving
human participants were in accordance with the ethical standards
of the institutional and/or national research committee and with the
1964 Helsinki declaration and its later amendments or comparable
ethical standards. Informed consent was obtained from all individual
participants included in the study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Padda SK, Burt BM, Trakul N, Wakelee HA (2014) Early-stage
non-small cell lung cancer: surgery, stereotactic radiosurgery, and
individualized adjuvant therapy. Semin Oncol 41(1):40–56. doi:10.
1053/j.seminoncol.2013.12.011
2. Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis
of concomitant versus sequential radiochemotherapy in locally ad-
vanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190.
doi:10.1200/jco.2009.26.2543
3. Schanne DH, Nestle U, Allgäuer M et al (2015) Stereotactic body
radiotherapy for centrally located stage I NSCLC: a multicenter
analysis. Strahlenther Onkol 191(2):125–132. doi:10.1007/s00066-
014-0739-5
4. Zehentmayr F, Wurstbauer K, Deutschmann H et al (2015) DART-
bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice
daily: high local control in early stage (I/II) non-small-cell lung
cancer. Strahlenther Onkol 191(3):256–263. doi:10.1007/s00066-
014-0754-6
5. Wurstbauer K, Zehentmayr F, Deutschmann H et al (2017) DART-
bid for loco-regionally advanced NSCLC: summary of acute and
late toxicity with long-term follow-up; experiences with pulmonary
dose constraints. Strahlenther Onkol 193(4):315–323. doi:10.1007/
s00066-016-1095-4
6. Simeonova-Chergou A, Jahnke A, Siebenlist K et al (2016) Au-
tomatically gated image-guided breath-hold IMRT is a fast, pre-
cise, and dosimetrically robust treatment for lung cancer patients.
Strahlenther Onkol 192(3):166–173. doi:10.1007/s00066-015-
0934-z
7. Korreman SS (2015) Image-guided radiotherapy and motion man-
agement in lung cancer. Br J Radiol 88(1051):20150100. doi:10.
1259/bjr.20150100
8. Shah AP, Kupelian PA, Willoughby TW, Meeks SL (2011) Expand-
ing the use of real-time electromagnetic tracking in radiation oncol-
ogy. J Appl Clin Med Phys 12(4):34–49. doi:10.1120/jacmp.v12i4.
3590
9. Booth JT, Caillet V, Hardcastle N et al (2016) The first patient treat-
ment of electromagnetic-guided real time adaptive radiotherapy us-
ing MLC tracking for lung SABR. Radiother Oncol 121(1):19–25.
doi:10.1016/j.radonc.2016.08.025
10. Krauss A, Nill S, Tacke M, Oelfke U (2011) Electromagnetic real-
time tumor position monitoring and dynamic multileaf collima-
tor tracking using a siemens 160 MLC: geometric and dosimetric
accuracy of an integrated system. Int J Radiat Oncol Biol Phys
79(2):579–587. doi:10.1016/j.ijrobp.2010.03.043
11. Fast MF, Nill S, Bedford JL, Oelfke U (2014) Dynamic tumor
tracking using the Elekta Agility MLC. Med Phys 41(11):111719.
doi:10.1118/1.4899175
12. Keall PJ, Colvill E, O’Brien R et al (2014) The first clinical imple-
mentation of electromagnetic transponder-guided MLC tracking.
Med Phys 41(2):020702. doi:10.1118/1.4862509
13. Krauss A, Nill S, Oelfke U (2011) The comparative performance
of four respiratory motion predictors for real-time tumour tracking.
Phys Med Biol 56(16):5303–5317. doi:10.1088/0031-9155/56/16/
015
14. Dürichen R, Wissel T, Ernst F, Schlaefer A, Schweikard A
(2014) Multivariate respiratory motion prediction. Phys Med Biol
59(20):6043–6060. doi:10.1088/0031-9155/59/20/6043
K
Strahlenther Onkol
15. Varian Medical Systems (2014) Beacon care package-lung, Instruc-
tions for use, LBL0146-001, 10 Oct
16. Seppenwoolde Y, Shirato H, Kitamura K et al (2002) Precise and
real-time measurement of 3D tumor motion in lung due to breathing
and heartbeat, measured during radiotherapy. Int J Radiat Oncol
Biol Phys 53(4):822–834. doi:10.1016/s0360-3016(02)02803-1
17. Bissonnette J-P, Franks KN, Purdie TG et al (2009) Quantifying in-
terfraction and intrafraction tumor motion in lung stereotactic body
radiotherapy using respiration-correlated cone beam computed to-
mography. Int J Radiat Oncol Biol Phys 75(3):688–695. doi:10.
1016/j.ijrobp.2008.11.066
18. Guckenberger M, Wilbert J, Meyer J, Baier K, Richter A, Flentje
M (2007) Is a single respiratory correlated 4D-CT study sufficient
for evaluation of breathing motion? Int J Radiat Oncol Biol Phys
67(5):1352–1359. doi:10.1016/j.ijrobp.2006.11.025
19. Imura M, Yamazaki K, Shirato H et al (2005) Insertion and fixa-
tion of fiducial markers for setup and tracking of lung tumors in ra-
diotherapy. Int J Radiat Oncol Biol Phys 63(5):1442–1447. doi:10.
1016/j.ijrobp.2005.04.024
20. Roman NO, Shepherd W, Mukhopadhyay N, Hugo GD, Weiss E
(2012) Interfractional positional variability of fiducial markers and
primary tumors in locally advanced non-small-cell lung cancer dur-
ing audiovisual biofeedback radiotherapy. Int J Radiat Oncol Biol
Phys 83(5):1566–1572. doi:10.1016/j.ijrobp.2011.10.051
21. Elsayad K, Kriz J, Reinartz G et al (2016) Cone-beam CT-guided
radiotherapy in the management of lung cancer: diagnostic and
therapeutic value. Strahlenther Onkol 192(2):83–91. doi:10.1007/
s00066-015-0927-y
K
